CAS · 19171-19-8
Product Overview
Pomalidomide is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Description | Yellow solid powder |
|---|---|
| Purity (HPLC) | 99.0% min |
| Identification | (1) MS (2) IR |
| Water | 1.0% max |
| Residue on ignition | 0.1% max |
| Heavy metals | 10ppm max |
| Residual solvent Methanol | 4000ppm max |
| Ethanol | 5000ppm max |
| Ethyl acetate | 4000ppm max |
| Acetone | 1000ppm max |
| Ordinary Impurities Single impurities | 0.1% max |
| Total impurities | 1.0% max |
Applications
1. Pharmaceutical Use: Treatment of Multiple Myeloma
Pomalidomide is an immunomodulatory drug (IMiD) approved for the treatment of relapsed or refractory multiple myeloma in patients who have received prior therapies.
It works as part of combination therapy to inhibit cancer cell growth.
2. Immunomodulatory and Anti-angiogenic Agent
Modulates the immune system by enhancing T-cell and natural killer (NK) cell function.
Inhibits tumor growth by blocking new blood vessel formation (anti-angiogenesis).
Induces apoptosis (programmed cell death) in malignant plasma cells.
3. Hematologic Malignancies
Investigated and used in clinical trials for other blood cancers, such as myelodysplastic syndromes and lymphomas.
Benefits
✅ Potent Anticancer Activity
Effective in patients resistant to other treatments such as lenalidomide and bortezomib.
✅ Immunomodulatory Effects
Enhances immune response against tumor cells, boosting the body's ability to fight cancer.
✅ Anti-inflammatory Properties
Reduces production of pro-inflammatory cytokines, which can contribute to tumor progression.
✅ Oral Administration
Convenient oral dosing improves patient compliance compared to intravenous therapies.
Conclusion
Pomalidomide (CAS 19171-19-8) is a next-generation immunomodulatory agent primarily used to treat relapsed and refractory multiple myeloma. Its ability to modulate the immune system, inhibit angiogenesis, and induce tumor cell death makes it a powerful therapy in hematologic malignancies. Despite its efficacy, careful management of side effects and strict safety protocols are essential due to its potent biological activity and teratogenic risk. Pomalidomide represents a critical advancement in targeted cancer therapy and continues to be studied for broader oncological applications.
Previous
Sunitinib Malate丨CAS 341031-54-7
Next